Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: May 26, 2022

NORMOCARB HF 25 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Normocarb Hf 25 patents expire, and what generic alternatives are available?

Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.

DrugPatentWatch® Generic Entry Outlook for Normocarb Hf 25

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 4, 2023. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for NORMOCARB HF 25
International Patents:4
US Patents:1
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:NORMOCARB HF 25 at DailyMed
Drug patent expirations by year for NORMOCARB HF 25
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NORMOCARB HF 25
Generic Entry Date for NORMOCARB HF 25*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for NORMOCARB HF 25

NORMOCARB HF 25 is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NORMOCARB HF 25 is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NORMOCARB HF 25

Sterile low bicarbonate dialysis concentrate solutions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dialysis Sups NORMOCARB HF 25 magnesium chloride; sodium bicarbonate; sodium chloride SOLUTION;INJECTION 021910-001 Jul 26, 2006 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NORMOCARB HF 25

See the table below for patents covering NORMOCARB HF 25 around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1347795 See Plans and Pricing
World Intellectual Property Organization (WIPO) 0249693 See Plans and Pricing
Australia 2620902 See Plans and Pricing
Canada 2365787 SOLUTIONS CONCENTREES STERILES FAIBLES EN BICARBONATE POUR DIALYSE (STERILE LOW BICARBONATE DIALYSIS CONCENTRATE SOLUTIONS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NORMOCARB HF 25

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1499331 13C0055 France See Plans and Pricing PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
1499331 SPC/GB13/034 United Kingdom See Plans and Pricing PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0984957 122012000017 Germany See Plans and Pricing PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
0984957 C300483 Netherlands See Plans and Pricing PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524
0984957 122012000051 Germany See Plans and Pricing PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 CR 2012 00035 Denmark See Plans and Pricing PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1020461 C300482 Netherlands See Plans and Pricing PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Medtronic
McKinsey
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.